Th1/2 Immune Response Signature Predicts Outcome after Dose-Dense Immunochemotherapy in Patients with High Risk Diffuse Large B-Cell Lymphoma - Results from Nordic Lymphoma Group Trials

Matias Autio, Suvi-Katri Leivonen, Judit Meszaros Jorgensen, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Harald Holte, Sirpa Leppä

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Article number4008
Number of pages2
Publication statusPublished - 7 Dec 2017
MoE publication typeNot Eligible
Event59th Annual Meeting of the American-Society-of-Hematology (ASH) - Atlanta, Gabon
Duration: 9 Dec 201712 Dec 2017

Cite this